Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-07-30

FDA Approved: ENSTILAR — Supplemental Application (LEO Pharma Inc.)

View source ↗

Summary

FDA approved a supplemental application for ENSTILAR (calcipotriene and betamethasone dipropionate) from LEO Pharma Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Enstilar (calcipotriene; betamethasone dipropionate)

Snippet

SUPPL AP for ENSTILAR (CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE)